Anti-Mouse CD20 Antibody (18B12)

Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 0) induces a modest, transient slowing of AB12 mesothelioma growth in BALB/c mice, with up to 60% reduction in tumor burden observed depending on treatment timing^[1].
Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 0) slows growth of established AB12 mesothelioma in BALB/c mice, with up to 70% reduction in tumor burden observed in mice with 7-day established tumors^[1].
Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 8 post-tumor inoculation) administered in combination with Ad.E7 vaccination induces marked regression of established TC1 lung cancer in C57BL/6 mice, with 67% of tumors completely regressing and cured mice resistant to rechallenge, accompanied by robust systemic and intratumoral tumor antigen-specific CD8⁺ T-cell responses^[1].
Anti-Mouse CD20 Antibody (18B12) (10 mg/kg; i.v.; single dose on day 0) induces sustained B-cell depletion in healthy mice, with >90% depletion of blood and lymph node B cells, 84% depletion of splenic B cells by day 7, and variable depletion of splenic B-cell subpopulations^[1].
Anti-Mouse CD20 Antibody (18B12) (5 mg/kg; i.v.; 3 doses on day 19, day 22, day 25 after reaching EAE score ≥2.5) potently depletes 94% of total splenic B cells and reduces CNS-infiltrating B cell infiltrates by up to 77% in wild-type C57BL/6 mice with chronic EAE, but does not improve clinical disease, serum antibody levels, or spinal cord myelination^[2].
Anti-Mouse CD20 Antibody (18B12) (30 mg/kg; i.p.; two doses at 1 hour and 6 hours after injury) reduces spinal cord tissue damage, improves hindlimb motor function, inhibits NF-κB pathway activation, lowers proinflammatory mediator and cytokine expression, and reduces immune cell infiltration/activation in a mouse model of SCI^[3].